| Literature DB >> 27992604 |
Takeshi Nishijima1, Katsuji Teruya1, Satoshi Shibata1, Yasuaki Yanagawa1, Taiichiro Kobayashi1, Daisuke Mizushima1, Takahiro Aoki1, Ei Kinai1, Hirohisa Yazaki1, Kunihisa Tsukada1, Ikumi Genka1, Yoshimi Kikuchi1, Shinichi Oka1, Hiroyuki Gatanaga1.
Abstract
BACKGROUND: The epidemiology of incident syphilis infection among HIV-1-infected men who have sex with men (MSM) largely remains unknown.Entities:
Mesh:
Year: 2016 PMID: 27992604 PMCID: PMC5161506 DOI: 10.1371/journal.pone.0168642
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1Patient enrollment process.
¶Syphilis was defined by Rapid Plasma Reagin ≥8 and positive Treponema pallidum latex agglutination. MSM: men who have sex with men.
Fig 2Incidence of syphilis among HIV-1-infected MSM during the observation period.
The incidence decreased slightly during the observation period, although this trend was not significant (p = 0.315). Upper and lower whiskers represent 95% confidence interval.
Baseline characteristics of the study patients.
| All patients (n = 671) | Patients with incident syphilis (n = 112) | Patients without incident syphilis (n = 559) | P value | |
|---|---|---|---|---|
| Age (years), median (IQR) | 36 (30–43) | 34 (27–38) | 37 (31–44) | <0.001 |
| CD4 count (/μl), median (IQR) | 238 (85–374) | 274 (152–404) | 228 (77–372) | 0.054 |
| HIV-1 viral load (log10/ml), median (IQR) | 4.77 (4.08–5.36) | 4.79 (3.99–5.28) | 4.77 (4.08–5.38) | 0.750 |
| On antiretroviral therapy, n (%) | 65 (10) | 11 (10) | 54 (10) | 1.000 |
| History of AIDS, n (%) | 202 (30) | 26 (23) | 176 (32) | 0.091 |
| History of syphilis, n (%) | 183 (27) | 53 (47) | 130 (23) | <0.001 |
| Anti- | 146 (22) | 36 (32) | 110 (20) | 0.003 |
| Hepatitis C RNA-positive, n (%) | 3 (0.4) | 1 (0.9) | 2 (0.4) | 0.422 |
| Hepatitis C antibody-positive, n (%) | 17 (3) | 3 (3) | 14 (3) | 1.000 |
| Hepatitis B surface antigen-positive, n (%) | 61 (9) | 12 (11) | 49 (9) | 0.476 |
| Exposure to hepatitis B virus, n (%) | 388 (58) | 78 (70) | 310 (56) | 0.006 |
| Ethnicity, n (%) | 0.370 | |||
| Japanese | 634 (95) | 106 (95) | 528 (94) | |
| Other Asians | 22 (3) | 2 (2) | 20 (4) | |
| Others | 15 (2) | 4 (3) | 11 (2) | |
| Illicit drug use, n (%) | 195 (29) | 43 (38) | 152 (27) | 0.022 |
| Injection drug use, n (%) | 51 (8) | 5 (5) | 46 (8) | 0.239 |
| Methamphetamine use, n (%) | 44 (7) | 10 (9) | 34 (6) | 0.294 |
| Bathhouse use, n (%) | 309 (46) | 57 (51) | 252 (45) | 0.320 |
| Incarceration due to illicit drugs, n (%) | 19 (3) | 6 (5) | 13 (2) | 0.109 |
| Health insurance status, n (%) | 0.485 | |||
| With insurance | 616 (92) | 106 (95) | 510 (91) | |
| No insurance | 10 (1) | 1 (1) | 9 (2) | |
| On social benefits | 45 (7) | 5 (4) | 40 (7) | |
| Follow-up period (years), median (IQR) | 3.80 (2.19–5.66) | 1.92 (1.11–3.45) | 4.21 (2.50–5.87) | <0.001 |
History of syphilis was defined as baseline positive TPHA and RPR titer <1:8. Exposure to HBV was defined as those either with positive HBsAg, anti-HBs, or anti-HBc
¶ The variable anti-amoeba antibody was missing in 21 (3%) patients.
* Two patients were vaccinated with hepatitis B vaccine and counted as no exposure to hepatitis B virus.IQR: interquartile range,
Stages and clinical features of incident syphilis (n = 112).
| Incident syphilis (n = 112) | |
|---|---|
| Early symptomatic syphilis | 69 (62%) |
| Skin rash | 50 (45%) |
| Oral/pharyngeal lesions | 8 (7%) |
| Genital lesions | 6 (5%) |
| Lymphadenopathy | 2 (2%) |
| Hepatotoxicity | 1 (1%) |
| Symptom unknown | 2 (2%) |
| Ocular syphilis | 2 (2%) |
| Latent syphilis | 41 (37%) |
| Early latent syphilis | 4 (4%) |
| Late latent syphilis | 20 (18%) |
| Latent syphilis diagnosed using stored serum samples | 17 (15%) |
Results of uni- and multi-variable analyses to estimate risk factors for incident syphilis infection.
| IR/1000 person-year | Univariable analysis (n = 671) | Multivarible analysis (n = 650) | |||||
|---|---|---|---|---|---|---|---|
| HR | 95% CI | P value | Adjusted HR | 95% CI | P value | ||
| Age¶ | |||||||
| <33 years | 60.1 | 3.1 | 1.83–5.42 | <0.001 | 3.9 | 2.15–7.00 | <0.001 |
| 33–40 years | 54.2 | 2.9 | 1.66–4.94 | <0.001 | 2.8 | 1.58–5.02 | <0.001 |
| >40 years | 18.8 | Ref | Ref | Ref | Ref | ||
| History of syphilis at baseline vs. no history | 86.6 vs. 29.7 | 2.8 | 1.96–4.13 | <0.001 | 3.0 | 2.03–4.47 | <0.001 |
| Baseline HBV exposure vs. -no exposure | 50.6 vs. 32.0 | 1.6 | 1.07–2.39 | 0.023 | 1.3 | 0.86–2.03 | 0.204 |
| Baseline anti-Eh-positive vs. negative | 63.3 vs. 36.0 | 1.8 | 1.17–2.62 | 0.006 | 1.8 | 1.17–2.68 | 0.007 |
| Baseline CD4 count (/μL) | 1.0 | 1.00–1.00 | 0.007 | 1.0 | 1.00–1.00 | 0.088 | |
| <200 | 29.4 | Ref | Ref | Ref | Ref | ||
| 200–349 | 50.7 | 1.7 | 1.08–2.72 | 0.023 | 1.4 | 0.85–2.21 | 0.194 |
| ≥350 | 59.6 | 2.0 | 1.27–3.13 | 0.003 | 1.6 | 1.00–2.53 | 0.050 |
| Baseline HIV-RNA load (per log10/ml increase) | 0.9 | 0.81–1.10 | 0.467 | ||||
| History of AIDS vs. no history | 31.0 vs. 48.7 | 0.6 | 0.41–0.99 | 0.044 | |||
| Illicit drug users vs. non-users | 59.0 vs. 36.8 | 1.6 | 1.08–2.32 | 0.018 | 1.4 | 0.91–2.00 | 0.136 |
| Injection drug users vs. non-users | 25.2 vs. 44.4 | 0.6 | 0.23–1.39 | 0.212 | |||
| Methamphetamine users vs. non-users | 67.5 vs. 41.5 | 1.6 | 0.84–3.07 | 0.156 | |||
| Incarceration due to drugs vs. no such history | 106.6 vs. 41.6 | 2.5 | 1.11–5.75 | 0.028 | |||
| Bathhouse users vs. non users | 46.6 vs. 40.9 | 1.0 | 0.73–1.48 | 0.815 | |||
* These variables were incorporated into the model for multivariate analysis.
History of syphilis was defined as baseline positive TPHA and RPR titer <1:8. Exposure to HBV was defined as those either with positive HBsAg, anti-HBs, or anti-HBc
IR: incident rate, HR: hazard ratio, CI: confidence interval, HBV: hepatitis B virus, anti-Eh: anti-Entamoeba histolytica antibody